First 10 pages of Supp thread doesn't mention Mitoq. I wonder what the LongeCity community thinks of Mitoq in 2017. Is this worth the money? Does it shorten lifespan? Better try other supps?
Edited by Forever21, 01 June 2017 - 09:55 PM.
Posted 01 June 2017 - 09:55 PM
First 10 pages of Supp thread doesn't mention Mitoq. I wonder what the LongeCity community thinks of Mitoq in 2017. Is this worth the money? Does it shorten lifespan? Better try other supps?
Edited by Forever21, 01 June 2017 - 09:55 PM.
Posted 27 July 2018 - 12:42 PM
Please be aware of this recent study entitled:
The targeted anti‐oxidant MitoQ causes mitochondrial swelling and depolarization in kidney tissue
https://www.ncbi.nlm...les/PMC5880956/
Any comments?
Posted 01 August 2018 - 10:26 PM
Please be aware of this recent study entitled:
The targeted anti‐oxidant MitoQ causes mitochondrial swelling and depolarization in kidney tissue
https://www.ncbi.nlm...les/PMC5880956/
Any comments?
Definitely a few comments!
We were very surprised when we saw this study but it turns out that they literally flooded the cells with MitoQ and any compound at a high enough concentration will mess with cell function. This is a low-quality study which just shows that high concentrations of hydrophobic TPP cations in vitro are accumulated and can cause swelling. In vitro experiments were done with high volume of buffer - neglecting accumulation. We know that MitoQ is protective against the kidney in several studies in vivo and also during organ storage. If you incubated the cells with 500 mM sucrose they'd die as well but that doesn't mean anything.
We are almost at the end of a clinical trial for Chronic Kidney Disease being run out of Delaware U and from what I understand it has gone well - more to follow on that soon. See study #9 https://clinicaltria...te=&city=&dist=
I have listed our previous kidney research below.
Mitochondria-targeted antioxidant MitoQ reduced renal damage caused by ischemia-reperfusion injury in rodent kidneys: Longitudinal observations of T2 -weighted imaging and dynamic contrast-enhanced MRI.
Liu X et al. Magn Reson Med. 2018 Mar;79(3):1559-1567. DOI: 10.1002/mrm.26772
Reactive oxygen species promote tubular injury in diabetic nephropathy: The role of the mitochondrial ROS-TXNIP-NLRP3 biological axis.
Han Y et al. Redox Biol. 2018 Feb 15;16: 32-46. DOI: 10.1016/j.redox.2018.02.013
Mitochondrial abnormality facilitates cyst formation in autosomal dominant polycystic kidney disease.
Ishimoto Y et al. Mol. Cell. Biol. 2017 Dec. 37: 24 e00337-17. DOI: 10.1128/MCB.00337-1
The mitochondria-targeted antioxidant MitoQ ameliorated tubular injury mediated by mitophagy in diabetic kidney disease via Nrf2/PINK1.
Xiao L et al. Redox Biol. 2017 Apr; 11: 297–311. DOI: 10.1016/j.redox.2016.12.022
Targeted mitochondrial therapy using MitoQ shows equivalent renoprotection to angiotensin converting enzyme inhibition but no combined synergy in diabetes.
Ward MS et al. Scientific Reports 2017. 7: 15190. DOI: 10.1038/s41598-017-15589-x
The swan-neck lesion: proximal tubular adaptation to oxidative stress in nephropathic cystinosis.
Galaretta CI et al. Am J Physiol Renal Physiol. 2015 May 15;308(10): F1155-66. DOI: 10.1152/ajprenal.00591.2014
Protection against renal ischemia–reperfusion injury in vivo by the mitochondria targeted antioxidant MitoQ.
Dare AJ et al. Redox Biol. 2015 Aug; 5: 163–168. DOI: 10.1016/j.redox.2015.04.008
Contribution of mitochondrial function to exercise-induced attenuation of renal dysfunction in spontaneously hypertensive rats.
Gu Q et al. Mol Cell Biochem. 2015 Aug;406(1-2):217-25. DOI: 10.1007/s11010-015-2439-6
Peroxynitrite induced mitochondrial biogenesis following MnSOD knockdown in normal rat kidney (NRK) cells.
Marine A et al. Redox Biol. 2014; 2: 348–357. DOI: 10.1016/j.redox.2014.01.014
Preclinical evaluation of the mitochondria-targeted antioxidant mitoquinone to treat sepsis-induced acute kidney injury.
Patil NK et al. FASEB J. 2013 27:1_supplement, 889.8-889.8 (LINK)
Prevention of diabetic nephropathy in Ins2+/−AkitaJ mice by the mitochondria-targeted therapy MitoQ.
Chacko BK et al. Biochem J. 2010 Nov 15; 432(Pt 1): 9–19. DOI: 10.1042/BJ20100308
I hope that clarifies the situation satisfactorily.
Thanks
Posted 04 September 2018 - 11:04 PM
The research on MitoQ looked sound enough for me to try it for a few months. I didn't notice any positive effects, but then nothing negative, either.
Personally, I prefer NR (nicotinamide riboside) as a mitochondrial energy supplement. However, I'm sure there are certain conditions or genetics where MitoQ would be a better choice.
0 members, 2 guests, 0 anonymous users